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Abstract The objective of the study was to investigate the
timing of central nervous system tissue atrophy in MS by
evaluating longitudinal retinal volume changes in a broadly
representative cohort with disease duration across the
entire arc of disease. In this longitudinal study, 135 patients
with MS and 16 healthy reference subjects underwent
spectral-domain optical coherence tomography (OCT) at
baseline and 2 years later. Following OCT quality control,
automated segmentation of the peripapillary retinal nerve
fiber layer (pRNFL), macular ganglion cell–inner plexi-
form layer (mGCIPL) and macular inner nuclear layer
(mINL) was performed. Generalized estimation equations
were used to analyze longitudinal changes and associations
with disease duration and clinical measures. Participants
had a median disease duration at baseline of 16.4 years
(range 0.1–45.4). Nearly half (44 %) of the MS patients
had previously experienced MS-related optic neuritis
(MSON) more than 6 months prior. The MS patients
demonstrated a significant decrease over 2 years of the
pRNFL (-1.1 lm, 95 % CI 1.4–0.7, p\ 0.001) and
mGCIPL (-1.1 lm, 95 % CI -1.4 to -0.8, p\ 0.001).
This thinning was most pronounced early in the course of
disease. These findings were irrespective of previous epi-
sodes of MSON. No consistent pattern of change was
observed for the mINL (-0.03 lm, 95 % CI -0.2 to 0.2,
p = 0.795). This longitudinal study demonstrated that
injury of the innermost retinal layers is found in MS and
that this damage occurs most rapidly during the early
stages of disease. The attenuation of atrophy with longer
disease duration is suggestive of a plateau effect. These
findings emphasize the importance of early intervention to
prevent such injury.
Keywords Multiple sclerosis  Optical coherence
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Introduction
Neuroaxonal loss is thought to be the primary substrate
underlying irreversible disability in multiple sclerosis (MS)
[1, 2]. However, the timing of neuroaxonal loss in MS is
unknown, with injury detected early [3, 4], but more severe
atrophy seen at later time stages [5–7]. With renewed
interest in developing treatments for progressive MS, and
interest in using atrophy measures as a potential biomarker
for clinical trials in progressive disease, it is crucially
important that the timing of tissue loss in MS is
established.
The anterior visual pathway provides a discrete
anatomically segregated system to investigate the dynam-
ics of neuroaxonal degeneration in MS [8, 9]. Injury to
axons and neurons in the retina can be quantified by retinal
spectral-domain optical coherence tomography (SD-OCT).
In addition, given the very high degree of reproducibility of
OCT, it is a potential method for tracking neuroaxonal loss
in MS at the level of the individual patient. Cross-sectional
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studies using SD-OCT have demonstrated evidence of
injury to the inner retinal layers in MS, such as the peri-
papillary retinal nerve fiber layer (pRNFL) and the macular
ganglion cell–inner plexiform layer (mGCIPL) [10–14],
and established that this injury is correlated with clinical
disability [11, 14–16]. Although retinal injury is most
severe in the later stages of the disease [17–20], retinal
axonal loss has been identified at early stages in the disease
course [21–24]. In a large-scale histology study, it was
shown that retinal injury not only includes axonal loss
(thinning of the pRNFL), but also a reduction in ganglion
cell density, demonstrating that inner retinal thinning in
MS reflects neuronal and axonal loss [20]. However, the
timing and pace of this injury, as with the rest of the central
nervous system, remains unknown. Therefore, the main
objective of this study was to investigate longitudinal
changes in pRNFL, mGCIPL and macular inner nuclear
layer (mINL) thickness over a 2-year period in a broadly
representative cohort of patients with a wide range of
disease duration in comparison with a healthy reference
group. This study was designed to evaluate whether the rate
of retinal layer thinning was dependent on disease duration
and if the pace of decline was correlated with clinical
disability.
Methods
This study was approved by the Medical Ethical Com-
mittees on Human Research of the VU University Medical
Center in Amsterdam, the Netherlands, and the University
of California, San Francisco Committee on Human
Research and is in accordance with the 1964 Declaration of
Helsinki. Written informed consent was obtained from all
subjects before study inclusion.
Study design and patient population
In order to investigate the dynamics of retinal layer injury,
a broadly representative cohort of patients with MS was
included in this longitudinal multi-center observational
study. Patients were enrolled from the VU University
Medical Center Amsterdam (VUMC) and University of
California, San Francisco (UCSF). Additionally, a sample
of healthy reference subjects was enrolled at the VU
University Medical Center Amsterdam for comparison.
All subjects were required to be between 18 and
80 years of age at the time of their baseline assessment.
MS patients were included if they had ‘high-risk CIS’
(defined as a history of one clinical demyelinating relapse
and at least one T2 hyperintensity typical of demyelination
on conventional brain MRI), relapsing remitting MS
(RRMS), secondary progressive MS (SPMS) or primary
progressive MS (PPMS) at the time of their baseline
assessment (as defined by Lublin–Reingold criteria) [25].
All subjects underwent clinical and OCT assessments at
baseline and were retested after 24 months (with a 4-month
visit window). Disease duration was defined as the time
from the first MS symptom. The Expanded Disability
Status Scale (EDSS) [26] was obtained by a certified
examiner. As potential swelling of the pRNFL during the
acute stages of MS related optic neuritis (MSON) may
confound OCT measurements, patients were excluded if
they had experienced symptomatic MSON 6 months prior
to either OCT measurement (baseline or follow-up),
according to a standard care protocol [27].
SD-OCT
Spectral Domain OCT (SD-OCT, Spectralis, Heidelberg
Engineering, Heidelberg, Germany) was performed in all
subjects at baseline and follow-up. In all scans, eye
tracking function was enabled for optimal image registra-
tion for averaging and follow-up [28]. For all follow-up
scans, automatic scan placement was used with the baseline
scan as reference. Data on the pRNFL were obtained using
a 12 ring scan placed around the optic nerve head
(Fig. 1A). Data on the macular area (mGCIPL and mINL)
were acquired using a macular volume scan (20 9 20
field, 49 B-scans) centered on the fovea (Fig. 1b).
Scans were excluded from the analyses if they did not
fulfill the revised quality control criteria (OSCAR-IB) [29].
In order to assess retinal pathology potentially resulting in
exclusion of OCT scans, the medical history of visual
symptoms was obtained from all patients and controls. In
particular, the assessment of history of symptomatic ON
was based on a standard protocol [27] and presence of
microcystic macular edema (MME) was assessed accord-
ing to diagnostic criteria described by Burggraaff et al.
[30]. Following this OCT quality control, automated seg-
mentation of the pRNFL, mGCIPL and mINL was per-
formed (Heidelberg Engineering, software version 1.7.1.0).
In addition, patients underwent clinical and ophthalmo-
logical evaluations for assessment of physical and visual
function. Baseline Multiple Sclerosis severity scale
(MSSS) scores were calculated for all patients, based on
baseline EDSS scores and disease duration.
Statistical analyses
Differences in disease duration and MSSS scores between
the two participating centers were tested using the non-
parametric Mann–Whitney U test and the independent
sample T test, respectively. Longitudinal changes in retinal
layer thickness were treated as absolute change scores (D,
delta) and relative change scores (percentage change) over
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the 2-year observation period. Change scores were used to
correct for biases caused by potential center-effects. All
analyses performed on eye-level (two separate eyes per
subject) were done using generalized estimation equations
(GEE), with an exchangeable correlation matrix and
adjustments for intra-subject inter-eye correlations. Addi-
tional adjustments for confounding factors such as age, sex
and disease type were performed as indicated. In order to
investigate the association with disease duration (defined
by time since first symptoms), this variable was categorized
into six groups based on the following cut-off values:
\5 years (N = 31), 5.0–9.9 years (N = 15),
10.0–14.9 years (N = 15), 15.0–19.9 years (N = 30),
20.0–24.9 (N = 17) and C25 years (N = 26).
Results
A total of 135 MS patients (7 high-risk CIS, 89 RRMS, 26
SPMS, 13 PPMS) were included in this longitudinal study
(N = 65 from VUMC and N = 70 from UCSF). At base-
line, patients had a median disease duration of 16.4 years,
with a range extending from 0.1 to 45.4 years. Although
disease duration at baseline was shorter for patients
enrolled at UCSF compared with VUMC (p\ 0.01,
Fig. 2a), disease severity (reflected by baseline MSSS
scores) was similar for patients from UCSF and VUMC
(p = 0.862, Fig. 2b).
Disease-modifying treatment was used by 58 patients
(43.0 %). Nearly half of all patients had previously expe-
rienced a clinically identified episode of unilateral
(30.4 %) or bilateral (most sequential) (13.3 %) MSON.
Presence of MME was not identified in any of the patients,
according to validated criteria [30]. Eight eyes were
excluded because of an episode of ON in the 6 months
prior to the OCT measurement. None of the included
patients had experienced an episode of ON between base-
line and follow-up measurement (more than 6 months prior
to the follow-up visit). An overview of the clinical and
demographic baseline data is shown in Table 1. Addi-
tionally, a sample (N = 16) of healthy reference subjects
was analyzed. Of these 16 subjects, 7 (44 %) were female
and they had a mean age of 50.7 years (SD 7.1). For all
subjects, the mean follow-up period was 24.4 months (SD
1.8).
Longitudinal changes in retinal layer thickness
Table 2 shows the mean individualized changes in pRNFL,
mGCIPL and mINL thicknesses over the 2-year observa-
tion period. Analyses with all MS eyes included, with a
correction for intra-subject inter-eye correlations, demon-
strated a significant decrease for both the pRNFL
(-1.1 lm) and mGCIPL (-1.1 lm, p\ 0.001 for both
comparisons) over a 2-year period. No significant changes
were observed for the mINL (-0.03 lm, p = 0.795).
Importantly, the observed thinning in pRNFL and mGCIPL
thickness in patients with MS was significantly larger
compared with the healthy reference group (p = 0.015 and
0.018, respectively), which showed -0.5 lm thinning for
the mGCIPL and -0.1 lm for pRNFL.
Subsequently, analyses stratified for MS eyes with
(MSON) and without (MSNON) symptomatic ON showed
that longitudinal changes in pRNFL, mGCIPL and mINL
thickness were similar for MSON and MSNON eyes. The
data demonstrate that previous episodes of MSON did not
Fig. 1 Scan and segmentation protocol for the OCT scans used in
this study. a The peripapillary ring scan (12 diameter) was used to
quantify the global mean retinal nerve fiber layer (pRNFL) thickness.
b The macular volume scan (20 9 20 field, 25 B-scans) was
centered on the fovea and used to assess thickness of the macular
ganglion cell ? inner plexiform layer (mGCIPL) and the inner
nuclear (mINL). The colored map represents a change in thickness
map with a 1, 2.22 and 3.45-mm EDTRS grid of which the eight
perimacular sectors were used in this study. The inner 1 mm circle
was excluded from the analysis because of absence of mGCIPL and
mINL in the fovea
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significantly affect the rate of thinning during the 2-year
observation period for pRNFL (-1.0 lm MSON vs
-1.4 lm MSNON, p = 0.125) mGCIPL (-0.9 lm MSON
vs -1.2 lm MSNON, p = 0.454) or mINL (-0.04 lm
MSON vs -0.06 lm MSNON, p = 0.895).
When the change scores for the 2-year observation
period were stratified according to disease type, a signifi-
cant difference emerged between relapsing MS and pro-
gressive MS (SPMS and PPMS combined) for the pRNFL
(p = 0.002), but not for the mGCIPL (p = 0.191) and
mINL (p = 0.540). In relapsing MS, significant thinning
was observed for the pRNFL (-1.4 lm, 95 % CI -1.8 to
-1.0), which was 14 times more than observed in the
reference group (-0.1 lm). In SPMS the rate of atrophy
over time for the pRNFL was significantly less (-0.3 lm,
95 % CI -1.0 to 0.4), but still three times larger than in
healthy reference subjects. For the mGCIPL, the atrophy
rate was slightly higher for the RRMS group (-1.1 lm,
95 % CI -1.5 to -0.7) compared to SPMS group
[-0.8 lm (-1.7 to 0.01), p = 0.053]. Regarding the
mINL, neither relapsing nor progressive MS patients
showed significant consistent changes over the 2-year
observation period across the cohort.
Fig. 2 Center specific distribution of a disease duration (years) and
b disease severity (MSSS score). Patients recruited from the VUMC
Amsterdam had a significantly longer disease duration [22.0 years
(SD 6.5)] compared with patients from UCSF [9.2 years (SD 9.6),
p\ 0.001]. Disease severity (MSSS score) was comparable for both
centers [UCSF 3.7 (SD 2.5) and VUMC 3.8 (SD 2.4), p = 0.862].
The horizontal dotted lines indicate the mean value per center
Table 1 Baseline characteristics
MS patients
N = 135
Sex (N [%] female) 101 (75.0 %)
Age (years, mean [SD]) 49.2 (SD 12.1)
Disease duration (years, median
[range], IQR)
16.4 [0.1–45.9],
IQR 16.3
Disease type (N [%])
High-risk CIS 7 (5.2 %)
RR 89 (65.9 %)
SP 26 (19.3 %)
PP 13 (9.6 %)
EDSS score (median [range], IQR) 3.0 [0.0–8.0],
IQR 2.5
MSSS score (mean [SD]) 3.75 (SD 2.4)
Disease-modifying treatment
Current 58 (43.0 %)
Interferon/glatiramer acetate 42 (72.4 %)
Natalizumab 9 (15.5 %)
Other 7 (12.1 %)
Past 25 (18.5 %)
Never 40 (29.6 %)
Unknown 12 (8.9 %)
History of optic neuritis (N [%])
None 72 (53.3 %)
Unilateral 41 (30.4 %)
Bilateral 18 (13.3 %)
Unknown 4 (3.0 %)
Time between baseline and follow-up
(months, mean [SD])
24.4 (SD 1.8)
OCT measurements
pRNFL (lm) 83.8 (SD 13.6)
mGCIPL (lm) 77.5 (SD 13.8)
mINL (lm) 38.9 (SD 3.6)
The number (percentage, %), median [range] and mean [standard
deviation, SD] are shown
CIS clinically isolated syndrome, RR relapsing remitting, SP sec-
ondary progressive, PP primary progressive, IQR interquartile range,
EDSS Expanded Disability Status Scale, MSSS multiple sclerosis
severity score, pRNFL peripapillary retinal nerve fiber layer, mGCIPL
macular ganglion cell ? inner plexiform layer, mINL macular inner
nuclear layer
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Changes in retinal layer thickness are more
pronounced early in the course of disease
Thinning of the pRNFL and mGCIPL was significantly
related to disease duration [b 0.05, 95 % CI 0.01–0.09,
p = 0.012 and b 0.06, 95 % CI 0.03–0.10, p = 0.001,
respectively (GEE, adjusted for inter-eye correlation,
optic neuritis and sex)]. Because change scores were
negative (which indicates thinning), the positive regres-
sion coefficients demonstrate that with a longer disease
duration, the rate of thinning becomes smaller. More
specifically, for every additional year of disease dura-
tion, the rate of thinning over a 2-year period, decreases
by 0.05 lm for the pRNFL and 0.06 lm for the
mGCIPL. Changes in mINL thickness did not show a
relationship with disease duration. The associations
between retinal layer thinning and disease duration are
shown in Fig. 3.
To investigate the association with disease duration in
more detail, disease duration was categorized into six
groups. Figure 4 shows the changes in retinal layer thick-
ness for all disease duration categories. Thinning of the
pRNFL and mGCIPL over the 2-year observation period
was most pronounced in patients with a shorter disease
duration. For the mINL, no such pattern was observed.
Discussion
This study showed that over a 2-year observation period,
significant thinning of the pRNFL and mGCIPL was
observed throughout the course of the disease, but that
Table 2 Individualized retinal layer changes over time, stratified by MS patients and healthy controls, MS eyes with and without previous ON
and relapsing MS and progressive MS
Absolute change (with 95 % CI) Relative change (with 95 % CI) p valueb
All MS eyesa
pRNFL lm (N = 239 eyes) 21.1 (21.4 to 20.7) 21.3 % (21.7 to 20.9) <0.001
mGCIPL lm (N = 248 eyes) 21.1 (21.4 to 20.8) 21.3 % (21.7 to 20.9) <0.001
mINL lm (N = 248 eyes) -0.03 (-0.2 to 0.2) -0.03 % (-0.6 to 0.5) 0.795
Healthy references
pRNFL (N = 31 eyes) -0.1 (-0.8 to 0.6) -0.1 % (-0.8 to 0.5) 0.797
mGCIPL (N = 30 eyes) 20.5 (20.9 to 20.1) 20.5 % (21.0 to 0.0) 0.021
mINL (N = 30 eyes) ?0.4 (-0.1 to 0.9) ?1.0 % (0.0 to 2.2) 0.082
MSNON eyes
pRNFL lm (N = 168 eyes) 21.0 (21.4 to 20.5) 21.1 % (21.5 to 20.6) <0.001
mGCIPL lm (N = 174 eyes) 20.9 (21.2 to 20.6) 21.1 % (21.5 to 20.7) <0.001
mINL lm (N = 174 eyes) -0.04 (-0.3 to 0.2) -0.03 % (-0.8 to 0.7) 0.769
MSON eyes
pRNFL lm (N = 64 eyes) 21.4 (22.0 to 20.7) 21.7 % (22.5 to 21.0) <0.001
mGCIPL lm (N = 74 eyes) 21.2 (22.0 to 20.5) 21.7 % (22.8 to 20.7) <0.001
mINL lm (N = 74 eyes) -0.06 (-0.5 to 0.3) -0.1 % (-1.1 to 0.9) 0.862
RRMS eyes
pRNFL (N = 170) 21.4 (21.8 to 21.0) 21.6 % (22.1 to 21.1) <0.001
mGCIPL (N = 176) 21.1 (21.5 to 20.7) 21.4 % (21.9 to 20.9) <0.001
mINL (N = 176) -0.08 (-0.3 to 0.2) -0.15 % (-0.8 to 0.5) 0.486
SPMS eyes
pRNFL (N = 48) -0.3 (-1.0 to 0.4) -0.3 (-1.2 to 0.6) 0.395
mGCIPL (N = 48) -0.8 (-1.7 to 0.01) -1.2 (-2.4 to -0.0) 0.053
mINL (N = 48) -0.1 (-0.5 to 0.3) -0.3 (-1.3 to 0.8) 0.598
PPMS eyes
pRNFL (N = 21) ?0.01 (-1.0 to 1.0) ?0.1 % (-1.1 to 1.2) 0.987
mGCIPL (N = 24) -0.4 (-1.5 to 0.6) -0.5 (-1.7 to 0.6) 0.448
mINL (N = 24) 0.8 (-0.3 to 1.8) ?2.0 (-0.7 to 4.7) 0.155
Bold values indicate p\ 0.05
pRNFL peripapillary retinal nerve fiber layer, mGCIPL macular ganglion cell ? inner plexiform layer, mINL macular inner nuclear layer, ON
optic neuritis, RRMS relapsing remitting MS, SPMS secondary progressive MS, PPMS primary progressive MS
a Scans which did not fulfill quality control criteria (OSCAR-IB) were excluded from the analyses
b Unadjusted GEE analysis (only intercept models) using the absolute change scores
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these changes were significantly more pronounced early in
the disease course. The attenuation of atrophy with longer
disease duration is suggestive of a plateau effect. Our
findings argue in favor of significant progressive neuronal
and axonal injury occurring during the earliest stages of
MS, providing support for early intervention to prevent or
forestall this injury.
Establishing the timing of neuroaxonal loss in MS is
crucial as we explore methods for assessing potential
therapeutics meant to treat progressive disease and prevent
this decline. It has been presumed in much of the literature
that neuroaxonal loss is the substrate underlying volume
loss on brain MRI. However, routinely used sequences on
brain MRI lack specificity in this regard, making the retina
an attractive additional site to monitor. Use of atrophy as a
biomarker in progressive MS trials is dependent on the
assumption that continued atrophy accumulates in the
progressive phase of disease. This study helps to establish
that the rate of atrophy in progressive disease may be lower
and helps inform timing and sample size calculations for
trials using OCT as an outcome.
In the present study, a longitudinal investigation of three
retinal layers was performed, the pRNFL, mGCIPL and
mINL. Firstly, our data showed significant thinning of the
pRNFL (-1.1 lm), over 10 times more than observed in
healthy reference subjects (-0.1 lm). This is in line with
previously reported findings of longitudinal changes in
pRNFL thickness obtained using time domain OCT [16,
18, 31]. In more recent studies using spectral-domain OCT,
Narayanan and colleagues reported an annualized decrease
in pRNFL of -1.49 lm for MSNON eyes, and -1.27 lm
for MSON eyes, but they did not assess for the impact of
disease duration or assess a cohort with a broad represen-
tation of disease durations [32]. Saidha and colleagues,
however, reported a considerably smaller yearly decrease
of -0.36 lm (MSON and MNON eyes together) [33].
Second, regarding the mGCIPL, we reported significant
thinning over a 2-year observation period (-1.1 lm). This
decrease in mGCIPL thickness, more than twice as much as
observed in the reference population, was similar for
MSON and MSNON eyes. In a recent longitudinal studies,
Narayanan and colleagues reported comparable findings,
with a yearly mGCIPL decrease of -0.53 lm in MSON
and -0.49 in MSNON eyes [32], whereas Saidha et al.
reported an annual change of -0.34 lm (MSON and
MSNON together) [33].
Third, with respect to the mINL, the present study
showed no consistent changes in patients with MS across
the cohort, independent of disease duration or disease type.
To our knowledge, no other longitudinal studies have
bFig. 3 Association between disease duration and change in retinal
layer thickness. Thinning of the pRNFL a and mGCIPL b is
significantly associated with disease duration. For the mINL (C), no
significant association was observed. * GEE, adjusted for inter-eye
correlation, optic neuritis, sex
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investigated changes in mINL thickness. Interestingly, in
human retinal postmortem samples, extensive loss of
neurons in the mINL has been demonstrated after about
20 years of disease duration [20]. This discrepancy
between in vivo and in vitro data would argue in favor of
mINL thinning as being a dynamic process, instead of a
constant process presenting a steady decrease during the
disease course. This hypothesis is further strengthened by
the reported increase in mINL thickness associated with
MME. The occurrence of MME in MS [34], is character-
ized by the presence of cystic areas of hyporeflectivity in
the mINL of the retina and it was shown that INL thickness
changes were dynamic and were associated with increased
disability [35]. Since none of the subjects experienced
MME during the study, the present data do not allow for
interpretation of the direct effect of MME on changes in
mINL thickness, but we do not rule out the possibility of
dynamic changes at a time scale not measured within the
present study.
Taken together, available longitudinal literature consis-
tently demonstrates progressive loss of pRNFL and
mGCIPL in patients with MS. It was, however, previously
unclear whether this inner retinal layer damage is a con-
tinuous process (as is often assumed with linear modeling),
or if the underlying process is dependent on the stage of the
disease. Previous studies have shown that retinal axonal
injury was already present early in the disease course of
MS [20–23]. Although the present data confirm this find-
ing, we have also conclusively shown that the rate of
pRNFL and mGCIPL thinning is dependent on disease
duration and is greatest in early phases of the disease.
Importantly, previous data on annual change of inner
retinal layer thickness are inconsistent. Given the findings
of the present study, we believe that annual change is
clearly influenced by disease duration. Therefore, the
inconsistent findings reported in literature are probably
partly caused by unaccounted differences in disease dura-
tion between study cohorts.
Furthermore, whereas pRNFL and mGCIPL thinning
were both present in eyes of patients with relapsing MS, the
eyes of SPMS patients only showed substantial thinning of
the mGCIPL. This finding is in concurrence with a previ-
ous longitudinal study by Henderson and colleagues, who
reported no significant decrease in pRNFL thickness after
an average follow-up of over 18 months in a cohort of
progressive MS patients [19]. This finding suggests that
although both neuronal and axonal injuries occur in the
relapsing phase of the disease, only subtle neuronal damage
continues in the progressive phase. Notwithstanding, this
finding should be interpreted with caution, as the effect was
bFig. 4 Mean change and 95 % CIs (error bars) in pRNFL (a),
mGCIPL (b), and mINL (c) per disease duration group. pRNFL and
mGCIPL thickness changes were dependent on disease duration, as
changes were most pronounced early in the disease course. The
horizontal dotted reference line indicates no change from baseline
[group sizes: \5 years (N = 31), 5.0–9.9 years (N = 15),
10.0–14.9 years (N = 15), 15.0–19.9 years (N = 30), 20.0–24.9
(N = 17) and C25 years (N = 26)]
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[although statistically significant (p = 0.015)], only mod-
estly stronger than observed in healthy references.
The present data support the large body of evidence on
the effects of previous episode of MSON on pRNFL and
mGCIPL thickness. Consistent with many other studies
[10, 36–38], we demonstrated that the eyes of patients who
experienced previous episodes of MSON showed signifi-
cantly more damage of both inner layers at baseline,
compared to unaffected (MSNON) eyes. The longitudinal
data of the present study, however, extend to these findings,
as we demonstrated that although the MSON eyes showed
significantly more injury at baseline, the rate of thinning
over time was similar for ON affected and unaffected eyes.
Consequently, while prior episodes of MSON act as a
major confounder in cross-sectional studies, its effect
seems considerably less important in longitudinal
investigations.
A major strength of the present study was the longitu-
dinal design. Although cross-sectional studies have pro-
vided very useful and important data on retinal layer injury
in MS, the longitudinal design of the present study, toge-
ther with the very broadly representative cohort of patients,
allowed for interpretation of the dynamics of retinal
changes in different stages of MS. Although the 2-year
observation period of the present study showed significant
changes, the absolute changes were relatively small.
Therefore, our current studies are focused on longer
observation periods (3–5 years) with repeated OCT and
clinical assessments. Our study may have several limita-
tions. First, the control group was relatively small.
Although this group was fairly homogeneous and similar to
the patient population, a larger sample would increase
statistical power. Similarly, although patients with a dis-
ease duration across the entire arc of disease were included,
those with a progressive disease course (SPMS and PPMS)
may have been underpowered, as the majority of patients
had relapsing remitting MS. Second, extensive low-con-
trast visual acuity and color vision testing was not included
in the present study. Both measures would provide
important information on visual functioning and should be
included in future studies [27].
In summary, this study showed that over a 2-year
observation period, significant thinning of the pRNFL and
mGCIPL, but not the mINL, was observed in patients with
MS throughout the course of disease. These changes in
pRNFL and mGCIPL were more pronounced early in the
disease course. The attenuation of atrophy with longer
disease duration suggests that the earliest phases of disease
provide the optimal time to prevent permanent neuroaxonal
injury.
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